Synaptogenix Non Current Liabilities Total from 2010 to 2025

SNPX Stock  USD 2.84  0.06  2.07%   
Synaptogenix Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total will likely drop to about 1.3 M in 2025. During the period from 2010 to 2025, Synaptogenix Non Current Liabilities Total regression line of annual values had r-squared of  0.66 and arithmetic mean of  787,788. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2010-12-31
Previous Quarter
1.4 M
Current Value
1.3 M
Quarterly Volatility
518.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Synaptogenix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synaptogenix's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 1.8 M or Interest Income of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.19 or PTB Ratio of 0.14. Synaptogenix financial statements analysis is a perfect complement when working with Synaptogenix Valuation or Volatility modules.
  
Check out the analysis of Synaptogenix Correlation against competitors.
For more information on how to buy Synaptogenix Stock please use our How to Invest in Synaptogenix guide.

Latest Synaptogenix's Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Synaptogenix over the last few years. It is Synaptogenix's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Synaptogenix's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
1.3M1.3M1.9M1.3M1.4M1.3M3%45%-33%15%-7%100%
       Timeline  

Synaptogenix Non Current Liabilities Total Regression Statistics

Arithmetic Mean787,788
Geometric Mean652,419
Coefficient Of Variation65.80
Mean Deviation468,384
Median413,081
Standard Deviation518,376
Sample Variance268.7B
Range1.5M
R-Value0.81
Mean Square Error97.8B
R-Squared0.66
Significance0.0001
Slope88,487
Total Sum of Squares4T

Synaptogenix Non Current Liabilities Total History

20251.3 M
20241.4 M
20231.3 M
20221.9 M
20211.3 M
20201.3 M

About Synaptogenix Financial Statements

Synaptogenix investors use historical fundamental indicators, such as Synaptogenix's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Synaptogenix. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total1.4 M1.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Synaptogenix Stock Analysis

When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.

Trending Assets

CYTH
Cyclo Therapeutics
0.89  -0.06  -6.32 
ALZN
Alzamend Neuro
0.96  -0.06  -5.88 
RVPH
Reviva Pharmaceuticals
1.56  -0.07  -4.29 
ANVS
Annovis Bio
2.13  -0.1  -4.48 
INMB
INmune Bio
8.59  -0.9  -9.48 
News Freq…Investor S…